Related Experiment Videos
Cyclophosphamide in lupus nephritis
1Rheumatology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium. houssiau@ruma.ucl.ac.be
Lupus
|March 1, 2005
Summary
Cyclophosphamide is a widely used treatment for lupus nephritis, despite ongoing debates about its optimal use. This review examines different cyclophosphamide regimens based on clinical trial data for lupus nephritis patients.
Area of Science:
- Nephrology
- Rheumatology
- Pharmacology
Background:
- Cyclophosphamide (CYC) is frequently used for lupus nephritis (LN) despite not being officially licensed for systemic lupus erythematosus (SLE).
- Extensive literature exists on CYC for LN, yet its application remains controversial.
- Key aspects like treatment duration, dosage, and administration route are subjects of ongoing debate.
Purpose of the Study:
- To review and discuss various cyclophosphamide (CYC) treatment regimens for lupus nephritis (LN).
- To analyze CYC protocols based on evidence from prospective randomized trials in LN patients.
Main Methods:
- Literature search on PubMed using keywords 'lupus nephritis' and 'cyclophosphamide'.
- Review of prospective randomized trials concerning CYC in lupus nephritis patients.
- Analysis of different CYC administration schedules and dosages.
Main Results:
- Cyclophosphamide (CYC) is a prevalent treatment for lupus nephritis (LN).
- Significant debate persists regarding the optimal use of CYC in LN treatment.
- Evidence from randomized trials informs the discussion on various CYC regimens.
Conclusions:
- The review synthesizes findings from clinical trials to discuss CYC regimens for LN.
- Understanding optimal CYC protocols is crucial for managing lupus nephritis.
- Further research and consensus are needed to refine CYC use in LN.